Meeting
2014 ASCO Annual Meeting
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Authors
Geoffrey Thomas Gibney
Moffitt Cancer Center, Comprehensive Melanoma Research Center, Tampa, FL
Geoffrey Thomas Gibney , Omid Hamid , Tara C. Gangadhar , Jose Lutzky , Anthony J. Olszanski , Thomas Gajewski , Bartosz Chmielowski , Peter D. Boasberg , Yufan Zhao , Robert Charles Newton , Peggy A Scherle , Jill Bowman , Janet Maleski , Lance Leopold , Jeffrey S. Weber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01604889
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3010)
DOI
10.1200/jco.2014.32.15_suppl.3010
Abstract #
3010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
First Author: Hatem Hussein Soliman
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
First Author: Saranya Chumsri
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Andrea Wang-Gillam